Dapagliflozin for Type 2 Diabetes Management

Introduction to Dapagliflozin

Dapagliflozin is a first-line SGLT2 inhibitor that reduces cardiovascular death, heart failure hospitalizations, and kidney disease progression in patients with type 2 diabetes, working through a unique insulin-independent mechanism that increases urinary glucose excretion while providing substantial cardiovascular and renal protection beyond glucose lowering 1, 2

Dapagliflozin reduces major adverse cardiovascular events (MACE) by 18-26% in patients with type 2 diabetes and established cardiovascular disease or risk factors, independent of its glucose-lowering effects 3, 2
The DAPA-HF trial demonstrated a 26% reduction in cardiovascular death or heart failure hospitalization (HR 0.74, 95% CI 0.65-0.85) in patients with heart failure regardless of diabetes status 2
The DELIVER trial showed an 18% reduction in worsening heart failure or cardiovascular death (HR 0.82, 95% CI 0.73-0.92) in patients with preserved ejection fraction 2

Dapagliflozin reduces the composite renal outcome by 44% (HR 0.56, 95% CI 0.45-0.68), including sustained eGFR decline, end-stage kidney disease, and renal death 2
The ADA/KDIGO consensus strongly recommends SGLT2 inhibitors as foundational therapy for patients with type 2 diabetes and chronic kidney disease 1

For Type 2 Diabetes with Normal to Mild Renal Impairment (eGFR ≥45 mL/min/1.73 m²): start dapagliflozin 10 mg once daily 1
For Type 2 Diabetes with Moderate Renal Impairment (eGFR 25 to <45 mL/min/1.73 m²): dapagliflozin 10 mg once daily is approved and effective for cardiovascular and renal protection 1
For Heart Failure (regardless of ejection fraction): dapagliflozin 10 mg once daily for all patients with symptomatic heart failure, independent of diabetes status 2
For Chronic Kidney Disease: dapagliflozin 10 mg once daily in patients with eGFR ≥25 mL/min/1.73 m² 1

The ADA/KDIGO consensus recommends adding a GLP-1 receptor agonist if glycemic targets are not met with metformin and/or SGLT2 inhibitor therapy 1
Dapagliflozin can be used in combination with metformin, GLP-1 receptor agonists, and DPP-4 inhibitors for complementary cardiovascular and renal benefits 1, 4

Do not initiate dapagliflozin for glycemic control if eGFR <25 mL/min/1.73 m² 1
For heart failure indication, do not initiate if eGFR <20 mL/min/1.73 m² 1
May continue therapy if eGFR declines below initiation threshold, as cardiovascular and renal benefits persist until dialysis 1
Glucose-lowering efficacy diminishes as eGFR declines, but cardiovascular and kidney benefits are preserved 1
Use caution when combining with diuretics 2
Monitor for signs of volume depletion, especially in elderly patients (≥65 years) who have higher rates of hypotension 2
Educate patients to seek medical attention for symptoms of ketoacidosis even with normal glucose levels 1